Comprehensive Characterization of Immune Landscape Based on Epithelial-Mesenchymal Transition Signature in OSCC: Implication for Prognosis and Immunotherapy.
Comprehensive Characterization of Immune Landscape Based on Epithelial-Mesenchymal Transition Signature in OSCC: Implication for Prognosis and Immunotherapy.
复制标题
基于 OSCC 上皮-间质转化特征的免疫景观的综合表征：对预后和免疫治疗的意义
DOI：
10.3389/fonc.2021.587862
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Wu T
中科院分区：
文献类型：
--
作者：
Zhang SY;Ren XY;Wang CY;Chen XJ;Cao RY;Liu Q;Pan X;Zhou JY;Zhang WL;Tang XR;Cheng B;Wu T
目前的解剖TNM分期分类未能捕捉到口腔鳞状细胞癌（OSCC）的免疫异质性。越来越多的证据表明，上皮-间质转化（EMT）与肿瘤免疫应答之间存在着密切的联系。在这项研究中，我们利用TCGA和GSE41613转录组数据，采用EMT特征将OSCC患者分为上皮型（E-）和间充质型（M-）。ESTIMATE和CIRBERSORT分析表明，EMT特征基因起源于大块组织的基质。m亚型肿瘤表现为“免疫热”，免疫细胞浸润比e亚型多。活性免疫细胞低浸润，非活性免疫细胞高浸润，免疫检查点高表达，表现出m亚型肿瘤的免疫抑制特征。此外，我们开发并验证了一种基于EMT评分、7个免疫检查点表达和TNM分期的新型预后分类器，可以提高当前临床参数的预测效率。总之，我们的研究结果提供了对肿瘤免疫异质性的更好理解，并可能有助于指导OSCC的免疫治疗。
Current anatomic TNM stage classification fails to capture the immune heterogeneity of oral squamous cell carcinoma (OSCC). Increasing evidence indicates the strong association between epithelial-mesenchymal transition (EMT) and tumor immune response. In this study, we employed an EMT signature to classify OSCC patients into epithelial- (E-) and mesenchymal- (M-) phenotypes using TCGA and GSE41613 transcriptome data. The ESTIMATE and CIRBERSORT analyses implied that the EMT signature genes originated from the stroma of the bulk tissue. The M-subtype tumors were characterized as “immune-hot” with more immune cell infiltration than the E-subtype ones. The low infiltration of active immune cells, the high infiltration of inactive immune cells, and the high expressions of immune checkpoints demonstrated an immunosuppressive characteristic of the M-subtype tumors. Moreover, we developed and validated a novel prognostic classifier based on the EMT score, the expressions of seven immune checkpoints, and the TNM stages, which could improve the prediction efficiency of the current clinical parameter. Together, our findings provide a better understanding of the tumor immune heterogeneity and may aid guiding immunotherapy in OSCC.
登录
查看更多内容
DOI：
10.1056/nejmoa1003466
发表时间：
2010-08-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者：
Urba WJ
影响因子：
5.2
作者：
Hirai M;Kitahara H;Kobayashi Y;Kato K;Bou-Gharios G;Nakamura H;Kawashiri S
通讯作者：
Kawashiri S
影响因子：
30.5
作者：
Finkin S;Yuan D;Stein I;Taniguchi K;Weber A;Unger K;Browning JL;Goossens N;Nakagawa S;Gunasekaran G;Schwartz ME;Kobayashi M;Kumada H;Berger M;Pappo O;Rajewsky K;Hoshida Y;Karin M;Heikenwalder M;Ben-Neriah Y;Pikarsky E
通讯作者：
Pikarsky E
影响因子：
7.2
作者：
Chen, Yu-Pei;Zhang, Jian;Ma, Jun
通讯作者：
Ma, Jun
DOI：
10.1158/1078-0432.ccr-15-1434
发表时间：
2016-07-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Lou Y;Diao L;Cuentas ER;Denning WL;Chen L;Fan YH;Byers LA;Wang J;Papadimitrakopoulou VA;Behrens C;Rodriguez JC;Hwu P;Wistuba II;Heymach JV;Gibbons DL
通讯作者：
Gibbons DL